The effects of nanocurcumin on Treg cell responses and treatment of ankylosing spondylitis patients: A randomized, double-blind, placebo-controlled clinical trial.
Majid AhmadiMehrzad HajialiloSanam DolatiShadi Eghbal-FardHanieh HeydarlouMahnaz GhaebiArezou GhassembaglouLeili Aghebati MalekiHossein Samadi KafilAmin KamraniBadrossadat RahnamaReza RikhtegarMehdi YousefiPublished in: Journal of cellular biochemistry (2019)
The findings suggested that dysregulation of Treg cells in PB influences the AS development and nanocurcumin therapy could regulate the Treg cells, and so could be useful in the treatment of AS and may be other autoimmune diseases. This study is registered with IRCT.ir, number IRCT2017052927520N7.
Keyphrases
- double blind
- clinical trial
- ankylosing spondylitis
- induced apoptosis
- placebo controlled
- cell cycle arrest
- end stage renal disease
- rheumatoid arthritis
- study protocol
- phase iii
- randomized controlled trial
- chronic kidney disease
- stem cells
- cell therapy
- squamous cell carcinoma
- oxidative stress
- disease activity
- open label
- peritoneal dialysis
- signaling pathway